Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)

NCT02807805 is registered in ClinicalTrials.gov with Mamta Parikh as lead sponsor.

NCT NCT02807805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02807805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)
Lead sponsor
Mamta Parikh
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 31, 2016
Completion date
December 31, 2025
Enrollment
37 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate carcinoma, recurrent prostate carcinoma, stage iv prostate cancer